Posted April 5, 2019
The recent fast track approval of a Johnson & Johnson subsidiary’s ketamine derived nasal spray called Spravato is raising a few eyebrows amid conscientious consumers. Marketed as one of the new depression therapies, Spravato is geared towards individuals who’ve tried two or more other treatments unsuccessfully, and according to recent research, this nasal spray for depression is indeed ‘effective.’ Read more.